Observational study of medical marijuana as a treatment for treatment-resistant epilepsies

9Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: Medical cannabis formulations with cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are widely used to treat epilepsy. We studied the safety and efficacy of two formulations. Methods: We prospectively observed 29 subjects (12 to 46 years old) with treatment-resistant epilepsies (11 Lennox–Gastaut syndrome; 15 with focal or multifocal epilepsy; three generalized epilepsy) were treated with medical cannabis (1THC:20CBD and/or 1THC:50CBD; maximum of 6 mg THC/day) for ≥24 weeks. The primary outcome was change in convulsive seizure frequency from the pre-treatment baseline to the stable optimal dose phase. Results: There were no significant differences during treatment on stable maximal doses for convulsive seizure frequency, seizure duration, postictal duration, or use of rescue medications compared to baseline. No benefits were seen for behavioral disorders or sleep duration; there was a trend for more frequent bowel movements compared to baseline. Ten adverse events occurred in 6/29 patients, all were transient and most unrelated to study medication. No serious adverse events were related to study medication. Interpretation: Our prospective observational study of two high-CBD/low-THC formulations found no evidence of efficacy in reducing seizures, seizure duration, postictal duration, or rescue medication use. Behavioral disorders or sleep duration was unchanged. Study medication was generally well tolerated. The doses of CBD used were lower than prior studies. Randomized trials with larger cohorts are needed, but we found no evidence of efficacy for two CBD:THC products in treating epilepsy, sleep, or behavior in our population.

References Powered by Scopus

Trial of cannabidiol for drug-resistant seizures in the dravet syndrome

1178Citations
N/AReaders
Get full text

Effect of cannabidiol on drop seizures in the lennox–gastaut syndrome

718Citations
N/AReaders
Get full text

Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention

483Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy

16Citations
N/AReaders
Get full text

Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis

7Citations
N/AReaders
Get full text

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Devinsky, O., Marmanillo, A., Hamlin, T., Wilken, P., Ryan, D., Anderson, C., … Todd, G. (2022). Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. Annals of Clinical and Translational Neurology, 9(4), 497–505. https://doi.org/10.1002/acn3.51537

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

56%

Researcher 4

25%

Professor / Associate Prof. 3

19%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

47%

Pharmacology, Toxicology and Pharmaceut... 4

21%

Psychology 3

16%

Biochemistry, Genetics and Molecular Bi... 3

16%

Save time finding and organizing research with Mendeley

Sign up for free